Assignee
XBIOTECH INC
CA·27 granted patents·19 pending applications·1,130 citations·filing 2007–2024
Top patents by PatentIndex Score
46 records- 0198US8034337B2Interleukin-1α antibodiesXBIOTECH INC·Filed 2009·Granted Oct 11, 2011·1k cites·1 claims
- 0296US9486523B2Compositions and methods for treating and preventing Staphylococcus aureus infectionsXBIOTECH INC·Filed 2016·Granted Nov 8, 2016·17 cites·8 claims
- 0395US9416172B2Compositions and methods for treating and preventing Staphylococcus aureus infectionsXBIOTECH INC·Filed 2015·Granted Aug 16, 2016·16 cites·8 claims
- 0494US9840558B2Human antibody specific for interleukin-1alphaXBIOTECH INC·Filed 2015·Granted Dec 12, 2017·9 cites·5 claims
- 0592US11370831B2Compositions and methods for treating and preventing Staphylococcus aureus infectionsXBIOTECH INC·Filed 2020·Granted Jun 28, 2022·2 cites·2 claims
- 0692US9783598B2Compositions and methods for treating and preventing Staphylococcus aureus infectionsXBIOTECH INC·Filed 2016·Granted Oct 10, 2017·7 cites·10 claims
- 0791US8784817B2Method for killing IL-1 alpha expressing cellsXBIOTECH INC·Filed 2013·Granted Jul 22, 2014·8 cites·2 claims
- 0891US8679489B2Inhibiting cell migrationXBIOTECH INC·Filed 2013·Granted Mar 25, 2014·8 cites·2 claims
- 0990US10214581B2Compositions and methods for treating and preventing Staphylococcus aureus infectionsXBIOTECH INC·Filed 2017·Granted Feb 26, 2019·5 cites·10 claims
- 1089US10202449B2Cachexia treatmentXBIOTECH INC·Filed 2017·Granted Feb 12, 2019·6 cites·3 claims
- 1187US10577410B2Compositions and methods for treating and preventing Staphylococcus aureus infectionsXBIOTECH INC·Filed 2019·Granted Mar 3, 2020·3 cites·11 claims
- 1287US9181338B2Human antibody specific for IL-1alphaXBIOTECH INC·Filed 2014·Granted Nov 10, 2015·4 cites·2 claims
- 1385US2025051436A1Arthritis TreatmentXBIOTECH INC·Filed 2024·Application pending·0 cites
- 1484US8956831B2Nucleic acids encoding a human monoclonal antibody that specifically binds to IL-1αXBIOTECH INC·Filed 2014·Granted Feb 17, 2015·3 cites·7 claims
- 1583US11773157B2Compositions and methods for treating and preventing Staphylococcus aureus infectionsXBIOTECH INC·Filed 2022·Granted Oct 3, 2023·0 cites·7 claims
- 1682US12116405B2Arthritis treatmentXBIOTECH INC·Filed 2022·Granted Oct 15, 2024·0 cites·9 claims
- 1780US9988447B2Treatment of diabetesXBIOTECH INC·Filed 2016·Granted Jun 5, 2018·1 cites·8 claims
- 1880US9902769B2Treatment of dermatological pathologiesXBIOTECH INC·Filed 2016·Granted Feb 27, 2018·1 cites·6 claims
- 1979US9809649B2Cachexia treatmentXBIOTECH INC·Filed 2012·Granted Nov 7, 2017·3 cites·14 claims
- 2075US9545441B2Treatment of diabetesXBIOTECH INC·Filed 2013·Granted Jan 17, 2017·1 cites·9 claims
- 2175US2024010711A1Compositions and methods for treating and preventing staphylococcus aureus infectionsXBIOTECH INC·Filed 2023·Application pending·0 cites
- 2274US2020071388A1Immunoglobulin Variable Region LibrariesXBIOTECH INC·Filed 2019·Application pending·0 cites
- 2373US9724409B2Treatment of inflammatory skin diseaseXBIOTECH INC·Filed 2012·Granted Aug 8, 2017·1 cites·11 claims
- 2468US9670483B2Immunoglobulin variable region librariesXBIOTECH INC·Filed 2016·Granted Jun 6, 2017·0 cites·5 claims
- 2566US2014099321A1Treating vascular disease and complications thereofXBIOTECH INC·Filed 2013·Application pending·0 cites
- 2665US2017233457A1Immunoglobulin Variable Region LibrariesXBIOTECH INC·Filed 2017·Application pending·0 cites
- 2763US9453217B2Identifying affinity-matured human antibodiesXBIOTECH INC·Filed 2015·Granted Sep 27, 2016·0 cites·5 claims
- 2863US9394536B2Identifying affinity-matured human antibodiesXBIOTECH INC·Filed 2015·Granted Jul 19, 2016·0 cites·7 claims
- 2963US2019389946A1Treatment of hidradenitis suppurativaXBIOTECH INC·Filed 2019·Application pending·0 cites
- 3061US12552860B2True human antibody specific for interleukin 1 alphaXBIOTECH INC·Filed 2023·Granted Feb 17, 2026·0 cites·2 claims
- 3161US12545724B2True human antibody specific for interleukin 1 alphaXBIOTECH INC·Filed 2023·Granted Feb 10, 2026·0 cites·2 claims
- 3261US12540177B2True human antibody specific for interleukin 1 alphaXBIOTECH INC·Filed 2023·Granted Feb 3, 2026·0 cites·2 claims
- 3361US12540176B2True human antibody specific for interleukin 1 alphaXBIOTECH INC·Filed 2023·Granted Feb 3, 2026·0 cites·2 claims
- 3460US2013287788A1Treatment of Psychiatric ConditionsXBIOTECH INC·Filed 2013·Application pending·0 cites
- 3559US2018057585A1Treating vascular disease and complications thereofXBIOTECH INC·Filed 2017·Application pending·0 cites
- 3659US2010040574A1TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIESXBIOTECH INC·Filed 2007·Application pending·0 cites
- 3758US2019169287A1Treatment of cancer with anti-il-1 alpha antibodiesXBIOTECH INC·Filed 2019·Application pending·0 cites
- 3858US2017002071A1Arthritis TreatmentXBIOTECH INC·Filed 2016·Application pending·0 cites
- 3956US2011070229A1Method of selecting a monoclonal antibody for administrationXBIOTECH INC·Filed 2010·Application pending·0 cites
- 4056US2011070230A1Method and devices for identifying and treating a subject who has developed an anti-antibody responseXBIOTECH INC·Filed 2010·Application pending·0 cites
- 4156US2011071276A1Method of modifying a monoclonal antibodyXBIOTECH INC·Filed 2010·Application pending·0 cites
- 4256US2011071054A1Panel of monoclonal antibody containing pharmaceutical compositionsXBIOTECH INC·Filed 2010·Application pending·0 cites
- 4354US2011008282A1IL-1alpha immunization induces autoantibodies protective against atherosclerosisXBIOTECH INC·Filed 2010·Application pending·0 cites
- 4450US2016159899A1Treatment of cancer with anti-il-1 alpha antibodiesXBIOTECH INC·Filed 2016·Application pending·0 cites
- 4548US2009191149A1IL-1alpha IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSISXBIOTECH INC·Filed 2007·Application pending·0 cites
- 4645US2013195877A1Treatment of cachexia by targeting interleukin-1 betaXBIOTECH INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when XBIOTECH INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →